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nanomedjournal.comAbstract
Liposomes functionalized with monoclonal antibodies or their antigen-binding fragments have attracted much attention as specific drug
delivery devices for treatment of various diseases including cancer. The conjugation of antibodies to liposomes is usually achieved by covalent
coupling using cross-linkers in a reaction that might adversely affect the characteristics of the final product. Here we present an alternative strategy
for liposome functionalization: we created a recombinant Fab antibody fragment genetically fused on its C-terminus to the hydrophobic peptide
derived from pulmonary surfactant protein D, which became inserted into the liposomal bilayer during liposomal preparation and anchored the Fab
onto the liposome surface. The Fab-conjugated liposomes specifically recognized antigen-positive cells and efficiently delivered their cargo, the
Alexa Fluor 647 dye, into target cells in vitro and in vivo. In conclusion, our approach offers the potential for straightforward development of
nanomedicines functionalized with an antibody of choice without the need of harmful cross-linkers.
© 2017 Elsevier Inc. All rights reserved.
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Figure 1. Analysis of the purified Fab fragments, either native or containing the neck domain peptide (NDP), by Western blotting. (A) The isolated CD48 and
CD59 Fabs containing the NDP and two variants of the CD48 Fab were resolved by SDS-PAGE under reducing (+β-ME) or non-reducing (−β-ME) conditions.
The proteins were blotted, blocked and developed with HRP-labeled so-called anti-mouse IgG + IgM antibodies, which, however, recognized the light chains
only as deduced from the analysis under reducing conditions in (A) and (B). (B) The membrane from (A) was reprobed with mouse anti-myc tag mAb (clone
9E10), recognizing the tagged Fab heavy chains, followed by the HRP-labeled anti-mouse antibodies. Similarly, the isolated CD59 Fab was resolved by
SDS-PAGE and detected with HRP-conjugated anti-mouse antibodies only (C) or (D) with anti-myc tag mAb as in (B).
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transport well both hydrophobic and hydrophilic drugs.1-3 For
these properties, liposomes are effective even as non-targeted
devices and their efficacy is best demonstrated by liposomal
doxorubicin Doxil®, the first nano-drug approved for cancer
treatment.4 Further improvement has been achieved with
functionalization of liposomal surface for active targeting. The
targeting ligands coupled to liposomal surface include proteins
(monoclonal antibodies (mAbs) or their fragments), aptamers,
vitamins, peptides or carbohydrates, which specifically recog-
nize cell-surface proteins that are overexpressed on targeted
cells.2-4 Antibodies or antibody fragments – most commonly
scFv and Fab – are frequently used due to their high specificity
and affinity. They can be covalently coupled using various
cross-linkers to either modified phospholipid head groups or
onto the free terminus of poly(ethylene glycol) chains, which
also serve as stealth. On the antibody side, the reactive groups of
amino acid side chains (e.g. thiols and primary amines) are
involved. Since antibodies may contain multiple reactive groups,
the conjugation reaction could lead to heterogeneous
mAb-liposomes, where antibody is aggregated on the liposomal
surface or is not properly oriented towards its antigen.2,5 In
addition, covalent reactions require the need of chemical
reagents that can potentially damage the targeting antibody or
the liposome.6
For these reasons, we searched for an alternative way to
functionalize liposomes with antibodies. We employed the
hydrophobic peptide derived from the α-helical neck domain of
the pulmonary surfactant protein D (SP-D) that we genetically
fused to the C-terminus of the Fab heavy chain. SP-D critically
regulates ultrastructure of surfactant membranes7 and its neckdomain shows affinity for phospholipids.8 Previously we
showed that the SP-D neck domain peptide efficiently anchored
folic acid into the liposomal membrane.9 Now we show that the
same strategy can be used to equip liposomes with targeting
proteins. We report here a full process of converting a mouse
mAb into a recombinant Fab antibody fragment with C-terminal
neck domain peptide (NDP), its expression in the yeast Pichia
pastoris and functionalization of liposomes with an isolated
Fab-NDP construct. As a proof-of-concept, we targeted two
well-characterized human glycosyl-phosphatidyl-inositol
(GPI)-anchored cell-surface molecules, CD48 and CD59, with
single-specific CD48 or CD59 Fab-functionalized liposomes as
well as with double-specific liposomes containing both Fabs and
demonstrated that the Fab-functionalized liposomes specifically
targeted antigen-positive cells.Methods
Fab antibody fragment cloning and expression in P. pastoris
The heavy and the light chains of the Fab antibody fragments
from the CD48 mAb MEM-102 and the CD59 mAb MEM-43/5
were cloned from the respective mAb-producing hybridomas.
The detailed cloning strategy, including tagging with the
C-terminal NDP peptide, as well as Fab expression, purification
and verification is provided in Supplementary data.
Liposome preparation
pH-sensitive liposomes composed of DOPE1,2-Dioleoyl-sn-
glycero-3-phosphoethanolamine)/CH (cholesterol)/DSPE-MPEG
Figure 2. Functionality of the purified Fab fragments, either naked or containing the NDP, was tested by flow cytometry. (A) Cell surface staining of human
CD48+ Jurkat cells versusmouse BW5147 thymoma cells. Cells were stained with the parental CD48 mAb (IgG1) or recombinant CD48 Fabs (two naked forms
of different lengths and the form containing the NDP) followed by visualization of binding using either APC-conjugated anti-mouse IgG + IgM antibodies or
AF647-conjugated anti-His-tag mAb. The specific staining is overlaid by the background staining of the isotype control mAb (filled gray histograms). (B) Cell
surface staining of CD59+ Jurkat cells versus mouse BW5147 cells. The binding of the CD59 Fab fragment containing the NDP was visualized as in (A). The
parental CD59 mAb (IgG2b) served as positive control.
Table 1
The size, polydispersity index (PdI) and ζ potential measurements of
liposomes.
Sample Z-average
size [nm]
PdI ζ potential
[mV]
Liposomes 128.0 ± 2.4 0.003 −1.12
CD48 Fab liposomes 125.9 ± 1.6 0.015 −1.76
CD59 Fab liposomes 126.8 ± 1.8 0.024 −0.965
CD48 + CD59 Fab liposomes 127.0 ± 2.0 0.008 −1.22
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sn-glycero-3-phosphoethanolamine]) were prepared using a thin
film hydrationmethod as previously described.9,10 Briefly, DOPE,
CH and DSPE-MPEG were dissolved in chloroform. After its
evaporation, the dried lipid film was dispersed in PBS containing
Fab-NDP antibody fragments and Alexa Fluor 647 (AF647). For
creation of bispecific liposomes, the concentration of theCD48 and
CD59 Fab-NDP fragments was 50% reduced to keep the liposome
loading constant. The mixture was vortex-mixed at r. t. to yield
multilamellar vesicles, which were then extruded through 200
nm pore size polycarbonate filters (Nucleopore, Merck
Millipore, Billerica, MA) followed by several passages through
100 nm polycarbonate filters (Nucleopore) to form large
unilamellar vesicles. The free AF647 dye and Fabs that were
not incorporated into liposomes were removed by gel filtration
(5 kD cut-off column; GE Healthcare, Little Chalfont, UK) and
dialysis (100 kD cut-off membrane; SERVA Electrophoresis,
Heidelberg, Germany).Determination of ζ potential, polydispersity index and size
Liposomes were characterized by the dynamic light scattering
using a Malvern zetasizer NS (Malvern Instruments, Malvern,
UK) as previously described.9Further methods describing liposome specificity and toxicity
tests are provided in Supplementary data.
Statistics
Statistical analysis and graphing was performed using Prism 5
(GraphPad Software, La Jolla, CA). Significance was accepted at
p b 0.05.Results
Fab antibody fragment cloning and expression
The CD48 and CD59 molecules are GPI-anchored proteins
that are localized in cholesterol-enriched membrane microdo-
mains called lipid rafts.11 CD59 is broadly expressed and serves
as an inhibitor of the cytolytic complement membrane attack
complex, hence called protectin.12 In contrast, CD48, also
known as BLAST-1, is rather restricted to immune cells,
including lymphocytes and antigen presenting cells, and its
expression is enhanced by inflammation.13 Both molecules have
been shown to provide costimulatory signals during T cell
activation.14-19 By employing mAbs specific for human CD48
(clone MEM-102) and human CD59 (clone MEM-43/5) we
previously scrutinized molecular mechanisms how these
GPI-anchored proteins were integrated into the T cell antigen
receptor/CD3 signaling and early T cell activation
events.14,16,18,20 In the present report, we used these mAbs as
targeting agents to allow liposome functionalization and highly
specific delivery of therapeutic drugs to CD48- and/or
CD59-positive cells. As a first step, we created recombinant
Fab antibody fragments of the aforementioned mAbs MEM-102
and MEM-43/5. For this, we isolated RNA from the respective
mAb-producing hybridoma cells, reverse transcribed it into
cDNA and amplified VH-CH1 and VL-CL regions of the
antibody chains by PCR. Amplification with a set of degenerate
forward primers specific for the beginning of the Framework
Figure 3. Fab antibody fragments are anchored in the membrane of
AF647-loaded liposomes through the NDP and exposed on the liposomal
surface. Control (empty) liposomes and liposomes harboring Fabs recogniz-
ing CD48, CD59 or both antigens were stained (or not) with FITC-labeled
anti-mouse IgG + IgM antibodies and analyzed by flow cytometry.
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class-specific reverse primer targeting the end of the CH1 or
the CL region, respectively, yielded several PCR products of the
correct length (ca 650 bp; data not shown). In addition, the heavy
chain of the CD48 mAb (of the IgG1 isotype) was amplified as a
slightly longer product, terminating after the first
cysteine-encoding codon at the beginning of the hinge region,
encompassing aa 1–221. Subsequent sequencing and in silico
analysis using IMGT/VQuest and IgBlast tools were used to
identify and exclude aberrant VH-CH1 and VL-CL sequences
that arose from unproductive rearrangement of the V, (D), J
alleles in the B cell or in the non-secreting myeloma fusion
partner used for hybridoma production.22,23 Next, the produc-
tively rearranged heavy and light chain sequences were re-cloned
into the Pichia expression vector pPICZαA, combined into the
single Fab expression vector encompassing both the heavy and
the light chain expression cassettes (Supplementary Figure 1, A)
and electroporated into the yeast Pichia pastoris.
Several zeocin-resistant Pichia clones with correctly
genome-integrated cDNAs of both Fab chains were tested for
the production of the Fab antibody fragments. By Western
blotting, positive signals were detected when analyzing Pichia
cell culture supernatants (data not shown) and the clones with the
highest secretion of Fabs into the cell culture media were selected
for large-scale cultivation and Fab purification. Subsequent
analysis of purified Fabs by Western blotting (Figure 1) revealed
that the CD48 Fab, the heavy chain of which encompassed the
VH-CH1 region (designated as aa 1–216), showed altered
migration at ≈70 kD (Figure 1, A right) under nonreducing
conditions. This was due to an incorrectly folded heavy chain
that predominantly migrated between 35 and 50 kD as revealed
by reducing SDS-PAGE and Western blotting with the anti-myc
mAb (Figure 1, B left). This finding was confirmed by treatment
of the purified CD48 Fab (aa 1–216) with recombinant
endoglycosidase F: the treated sample showed the same altered
migration as the non-treated one (data not shown) indicating that
the altered migration is not due to increased glycosylation but
due to conformation. Nevertheless, this Fab variant proved
functional in the flow cytometry analysis, because it stainedpositively human CD48-positive (CD48+) Jurkat T cells but not
mouse BW5147 thymoma cells (Figure 2, A left). In contrast,
the CD48 Fab variant with an additional cysteine in the heavy
chain (designated as aa 1–221) showed improved folding,
resulting in appearance of the≈50 kD band under non-reducing
conditions (Figure 1, A right), correlating with the increased
proportion of the correctly folded heavy chain migrating at ≈30
kD under reducing conditions (Figure 1, B left). Increased
folding resulted in improved binding to the CD48+ Jurkat cells,
when ≈54% Jurkat cells scored positively comparing to 31%
using the CD48 Fab (aa 1–216). For these reasons, the longer
variant of the CD48 Fab was chosen for further studies. The
CD59 Fab predominantly migrated at ≈50 kD under
non-reducing conditions (Figure 1, C) despite higher molecular
weight bands of the heavy chain as revealed by Western
blotting with the anti-myc mAb (Figure 1, D). It reacted only
with the CD59+ Jurkat T cells but not with the BW5147 cells
(Figure 2, B).
Generation of Fab antibody fragments with the
hydrophobic peptide
To equip the Fab antibody fragments with the hydrophobic
peptide derived from human SP-D (aa 242–248; QAAFSQY),
we genetically fused the C-terminus of the Fab heavy chains
with a modified peptide and a linker with an N➜C sequence
DRDDQAAWFSQY that we called the neck domain peptide
(NDP; Supplementary Figure 1, B). Previously, NDP was
successfully used to anchor folate into the lipid bilayer of the
liposomes without affecting liposomal integrity.9 Further,
bioinformatic analysis of the NDP-heavy chain constructs
revealed that NDP is extended away from the Fab variable and
constant domains (Supplementary Figure 2), indicating that
the Fab fragments should be efficiently inserted into the
liposomal membrane via the C-terminal hydrophobic peptide,
with the N-terminal antigen-binding sites well exposed.
Indeed, introducing NDP into the Fab sequences had no
detrimental effect onto the Fab folding (Figure 1, A and B) or
their functionality (Figure 2, A right, 2, B right). However, the
direct comparison of the CD48 Fab-NDP and CD59 Fab-NDP
constructs revealed higher affinity of the CD48 Fab-NDP to
its respective antigen (Supplementary Figure 3) as well as its
preferential recognition by our anti-mouse IgG + IgM
secondary reagent (Figure 2).
Liposome functionalization with the Fab-NDP fragments
Fab-functionalized pH-sensitive liposomes were prepared by
self-assembly when the dried lipid film was dispersed in PBS
containing AF647 and the NDP-equipped Fabs specific to the
CD48 or the CD59 molecule. Since both CD48 and CD59 reside
in lipid rafts and were shown to associate with each other in
human T cells,24 we also prepared bispecific liposomes
harboring both CD48 and CD59 Fab fragments to learn whether
these would preferentially target CD48+CD59+ cells. Control
liposomes were prepared without any additional protein,
carrying only AF647 as a cargo. Based on the dynamic light
scattering measurements (Table 1), all four preparations had a
similar size of around 125–130 nm and a very narrow size
Figure 4. Liposomes with incorporated CD48 Fab, CD59 Fab or both Fabs are specifically binding to cells in an antigen-dependent manner, without cytotoxic
effects. (A) Surface expression of the CD48 and CD59 molecules on Jurkat T cells and the mouse BW5147 cells (overexpressing either none, one or both
antigens) was determined by flow cytometry following costaining with AF555-labeled CD48 mAb (MEM-102) and AF647-labeled CD59 mAb (MEM-43/5).
(B) The indicated liposome samples were added to cells from (A) at 100 μg.mL−1 for 30 min on ice. After washing the liposomal binding to the cells was
visualized by FITC-labeled anti-mouse IgG + IgM antibodies and analyzed by flow cytometry. (C) To determine liposome cytotoxic effects, the viability of
CD48+CD59+ Jurkat T cells was assessed after 24 h contact with liposomal formulations and compared with the untreated (negative control) and 30%
DMSO-treated cells (positive control). Data are mean ± SEM from 3 experiments. ***p b 0.001, by one-way ANOVA.
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were monodisperse. The ζ potentials of the different preparations
were also similar and close to 0 mV. To test the presence of the
Fabs on the liposomal surface, we incubated them with
FITC-labeled anti-mouse IgG + IgM antibodies and analyzed
binding by flow cytometry. The anti-mouse antibodies
recognized a significant proportion of the liposomes equipped
with the Fabs but did not bind control liposomes (Figure 3).
Also by ELISA, control liposomes were not recognized by the
secondary antibody, while the Fab-functionalized liposomes
contained 3.38±0.50 μg Fab/1 mg liposome (for CD48 Fab
liposomes), 3.76±0.21 μg Fab/1 mg liposome (for CD59 Fab
liposomes) or 4.18±1.72 μg Fab/1 mg liposome (for
double-functionalized liposomes). Further, the flow cytometry
analysis revealed that all preparations were highly loaded with the
AF647 dye, though the Fab-equipped liposomes were loaded to a
lesser degree than the control ones (Figure 3).
Functional evaluation of the Fab-functionalized liposomes
To verify the specificity of the prepared liposomal formula-
tions, we used CD48+CD59+ Jurkat T cells, negative BW5147
cells and also BW5147 cells transduced with either one or both
antigens (Figure 4, A). The cells were incubated with the
liposomes for 30 min on ice and liposomal binding to the cells
was detected using FITC-labeled anti-mouse IgG + IgM anti-
bodies (Figure 4, B). The Fab-functionalized liposomes correctly
bound to the surface bearing the respective antigens:CD48-functionalized liposomes reacted with CD48+CD59+
Jurkat and CD48+CD59− and CD48+CD59+ BW5147 cells
but not with CD48−CD59+ or parental BW5147 cells.
Conversely, the CD59-functionalized liposomes reacted only
with double positive Jurkat and BW5147 cells and with CD48−
CD59+ BW5147 cells. The bispecific liposomes reacted with all
cells expressing either the CD48 or the CD59 molecule, though
the binding to the CD48−CD59+ BW5147 cells was weak. From
these results we concluded that the bispecific liposomes
predominantly bound through the CD48 Fab moiety that had
shown higher affinity than the CD59 Fab (Figure 2, A and B and
Supplementary Figure 3).
Since cytotoxicity is a major issue in nanodevice
technology,1,25 we tested the prepared liposomal formulations
with the CD48+CD59+ Jurkat T cells. After 24 h we saw no
detrimental effects on cell viability even when we incubated
the cells with the high liposomal concentration of 1 mg.mL−1
(Figure 4, C).
To scrutinize cellular uptake of our liposomes, we incubated
the control and CD48+CD59+ BW5147 cells with control or
Fab-functionalized liposomes and counterstained them with
anti-mouse AF488-labeled secondary antibodies on ice. Further
steps were performed at r. t. to allow slow internalization of the
liposomes. Confocal microscopy revealed that the
Fab-functionalized liposomes bound to the surface of the
CD48+CD59+ but not to control BW5147 cells (Figure 5, A).
They also appeared to readily release their cargo, the AF647 dye,
Figure 5. Liposomes with incorporated Fabs efficiently deliver AF647 into antigen-positive cells. (A) Confocal laser scanning microscopy images of control and
CD48+CD59+ BW5147 cells after incubation with the indicated AF647-loaded (in magenta) liposomes (100 μg.mL−1 for 30 min on ice) followed by
immunostaining (30 min on ice) with FITC-labeled secondary antibodies (in green). Cells were washed, fixed and mounted at r. t. Scale bar represents 20 μm. (B)
Liposome uptake by the control and CD48+CD59+ BW5147 cells at 37 °C over time was monitored by flow cytometry. In the graph, the ratio between the uptake
by the CD48+CD59+ BW5147 cells versus control BW5147 cells is shown. To account for the higher AF647 loading of the control liposomes (see Figure 3), the
fluorescence of cells incubated with the Fab-functionalized liposomes was further normalized to fluorescence of the control liposome sample at each time point.
Values represent mean ± SEM of two experiments. *p b 0.05, by one-way ANOVA.
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because the target cells turned positive whereas the control
BW5147 cells remained negative. AF647 staining of both cell
types upon encountering of control liposomes was similar and
higher than with the Fab-functionalized liposomes that might
have been caused by the higher dye loading of the control
liposomes (Figure 3). To quantify the specific uptake of the
control and Fab-functionalized liposomes, we added them to the
control and CD48+CD59+ BW5147 cells and monitored the
increase in AF647 fluorescence over time (Figure 5, B). To some
degree, both cell types took in the cargo of all types of liposomes
tested. Nevertheless, only the Fab-functionalized liposomes were
preferentially taken up by the CD48+CD59+ BW5147 cells
(Figure 5, B) and fluorescence gradually increased over time.
The most robust specific uptake was detected with the CD48
Fab-functionalized liposomes, which was in line with their
highest reactivity in the cell surface binding assay (Figure 4, B).
Additionally, we made a larger scale preparation of control
and CD48 Fab-functionalized liposomes that were equally
loaded with AF647 and also not cytotoxic (Supplementary
Figure 4, A and B). We thoroughly tested them using an array of
human CD48 molecule positive (human Raji B cells, human
Jurkat T cells, mouse BW5147 thymoma cells expressing the
human CD48 molecule) and human CD48 molecule negative
(mouse thymoma BW5147 cells, human myeloerythroid K-562
cells) cell lines, and observed the preferential uptake of the CD48
Fab-functionalized liposomes only by the CD48+ cells (Supple-
mentary Figure 4, C). Nevertheless, a basal liposomal uptake
over time was detectable with each cell line that was higher than
the uptake of free AF647.
Lastly, we tested the CD48 Fab liposomes in vivo for their
ability to specifically recognize CD48+ Raji B cell tumor
xenografts implanted on the chest of nude mice. Strikingly, we
observed the preferential AF647 accumulation in the tumor area
only when CD48 Fab-functionalized liposomes, but not control
liposomes were injected intravenously via the tail vein (Figure 6, A
and B). In one mouse where the tumor had grown to a size of only
20 mm3, the CD48 Fab liposomes also recognized the axillarylymph nodes (right mouse in Figure 6, A). This was because the
Raji B cells disseminated there as found by analysis of the lymph
nodes using a human CD19 mAb.Discussion
In this study, we have successfully developed a method to
convert mAbs into recombinant Fabs and efficiently produced
them in P. pastoris. P. pastoris is a popular host for heterologous
protein expression for several reasons: cost effectiveness, easy
genetic manipulation, availability of various vectors that allow
tightly regulated expression from inducible promoters and
especially production of high levels of correctly folded
heterologous proteins that contain correct disulfide bonds, are
proteolytically processed and glycosylated, similarly to mam-
malian proteins.26,27 While the production of scFv fragments in
P. pastoris was easily achieved,28 previous studies have shown
that Fab expression was more challenging and observed only in
the weaker constitutive expression system driven by the pGAP
promoter but not in the strong methanol-inducible system that we
used.29 In our hands, both native Fabs and Fabs equipped with
the neck domain peptide (NDP) on the C-terminus of the Fab
heavy chain expressed well and were highly functional.
We previously demonstrated that the hydrophobic NPD
inserts deeply into the lipid bilayer and anchors folate onto
liposomal surface.9 Also others have used hydrophobic peptides
derived from bacteriophages and genetically fused them to
targeting peptides to functionalize liposomes.30,31 Now we show
that NDP anchors onto liposomes without the need of harmful
cross-linkers not only small ligands but also Fabs with the
antigen-binding site well exposed. The resulting liposomes, as
demonstrated by the CD48- and CD59-Fab liposomes and
double-specific liposomes containing both Fabs, are highly
specific to the respective antigen-positive cells. Furthermore,
these liposomes are able to efficiently deliver the liposome cargo,
the AF647 dye, into the antigen-positive cells, both in vitro and
in vivo. This may be due to the fact that the CD59 and CD48
Figure 6. Liposomes with incorporated CD48 Fab efficiently target CD48+ Raji tumor xenografts. (A) AF647-labeled CD48 Fab- or control liposomes were
injected into nude mice with subcutaneously implanted Raji cells on the chest. Thirty minutes later we imaged the mice using an in vivo imager. Red-to-yellow
scale shows the intensity of AF647 fluorescence, blue ovals depict the areas that were quantified in (B) and blue arrows indicate measurable tumors. CD48 Fab
liposomes targeted either tumor mass or axillary lymph nodes (blue asterisk) with disseminated Raji cells. Additionally, we observed AF647 accumulation in the
bladder of all mice (green arrows), an indication of the fast renal clearance. (B) Quantification of AF647 fluorescence on the chest of mice injected with either
control or CD48 Fab liposomes. Values represent mean ± SEM. **p b 0.01, by unpaired two-tailed t test.
129A. Ohradanova-Repic et al / Nanomedicine: Nanotechnology, Biology, and Medicine 14 (2018) 123–130molecules, similarly to other GPI-anchored molecules, easily
internalize through the clathrin-independent mechanism.32
Previous studies showed that therapeutic efficacy of
antibody-targeted liposomal drugs was improved when the
liposomes targeted internalizing epitopes. For instance,
doxorubicin-loaded CD19 mAb-conjugated liposomes targeting
the internalizing B cell-specific molecule CD19 showed higher
degree of internalization and cytotoxicity in human B-lymphoma
cells than doxorubicin-loaded CD20 mAb-conjugated liposomes
against the non-internalizing molecule CD20.33
In conclusion, the use of liposomes, decorated with a
hydrophobic peptide-anchored antibody fragment of choice
against an internalizing antigen, and loaded with a therapeutic
drug, opens new avenues for efficient treatment of various
human diseases.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2017.09.003.
References
1. Sanvicens N, Marco MP. Multifunctional nanoparticles – properties and
prospects for their use in human medicine. Trends Biotechnol
2008;26:425-33.
2. Sawant RR, Torchilin VP. Challenges in development of targeted
liposomal therapeutics. AAPS J 2012;14:303-15.
3. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-
targeted liposome design: challenges and fundamental considerations.
Trends Biotechnol 2014;32:32-45.
4. Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-
Mello A. Nanomedicine applied to translational oncology: a future
perspective on cancer treatment. Nanomedicine 2016;12:81-103.5. Wang R, Xiao R, Zeng Z, Xu L, Wang J. Application of poly(ethylene
glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copol-
ymers and their derivatives as nanomaterials in drug delivery. Int J
Nanomedicine 2012;7:4185-98.
6. Nobs L, Buchegger F, Gurny R, Allemann E. Current methods for
attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci
2004;93:1980-92.
7. Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, et al.
Altered surfactant homeostasis and alveolar type II cell morphology in
mice lacking surfactant protein D. Proc Natl Acad Sci U S A
1998;95:11869-74.
8. Kishore U, Wang JY, Hoppe HJ, Reid KB. The alpha-helical neck region
of human lung surfactant protein D is essential for the binding of the
carbohydrate recognition domains to lipopolysaccharides and phospho-
lipids. Biochem J 1996;318(Pt 2):505-11.
9. Nogueira E, Mangialavori IC, Loureiro A, Azoia NG, Saarria MP,
Nogueira P, et al. Peptide anchor for folate-targeted liposomal delivery.
Biomacromolecules 2015;16:2904-10.
10. Nogueira E, Lager F, Le Roux D, Nogueira P, Freitas J, Charvet C, et al.
Enhancing methotrexate tolerance with folate tagged liposomes in
arthritic mice. J Biomed Nanotechnol 2015;11:2243-52.
11. Horejsi V. The roles of membrane microdomains (rafts) in T cell
activation. Immunol Rev 2003;191:148-64.
12. Meri S,MorganBP,DaviesA,DanielsRH,OlavesenMG,WaldmannH, et al.
Human protectin (CD59), an 18,000-20,000MWcomplement lysis restricting
factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology
1990;71:1-9.
13. McArdel SL, Terhorst C, Sharpe AH. Roles of CD48 in regulating
immunity and tolerance. Clin Immunol 2016;164:10-20.
14. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H. GPI-
anchored cell-surface molecules complexed to protein tyrosine kinases.
Science 1991;254:1016-9.
15. Korty PE, Brando C, Shevach EM. CD59 functions as a signal-
transducing molecule for human T cell activation. J Immunol
1991;146:4092-8.
16. Stulnig TM, Berger M, Sigmund T, Stockinger H, Horejsi V, Waldhausl
W. Signal transduction via glycosyl phosphatidylinositol-anchored
proteins in T cells is inhibited by lowering cellular cholesterol. J Biol
Chem 1997;272:19242-7.
130 A. Ohradanova-Repic et al / Nanomedicine: Nanotechnology, Biology, and Medicine 14 (2018) 123–13017. Kato K, Koyanagi M, Okada H, Takanashi T, Wong YW, Williams AF,
et al. CD48 is a counter-receptor for mouse CD2 and is involved in T cell
activation. J Exp Med 1992;176:1241-9.
18. Muhammad A, Schiller HB, Forster F, Eckerstorfer P, Geyeregger R,
Leksa V, et al. Sequential cooperation of CD2 and CD48 in the buildup
of the early TCR signalosome. J Immunol 2009;182:7672-80.
19. Lipp AM, Juhasz K, Paar C, Ogris C, Eckerstorfer P, Thuenauer R, et al.
Lck mediates signal transmission from CD59 to the TCR/CD3 pathway
in Jurkat T cells. PLoS One 2014;9:e85934.
20. Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E,
Howorka S, et al. Single-molecule microscopy reveals heterogeneous
dynamics of lipid raft components upon TCR engagement. Int Immunol
2007;19:675-84.
21. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, et
al. Molecular characterization of murine humoral immune response to
botulinum neurotoxin type a binding domain as assessed by using phage
antibody libraries. Infect Immun 1997;65:3743-52.
22. Vidarsson G, van de Winkel JG, van Dijk MA. Multiplex screening for
functionally rearranged immunoglobulin variable regions reveals
expression of hybridoma-specific aberrant V-genes. J Immunol Methods
2001;249:245-52.
23. Irani Y, Tea M, Tilton RG, Coster DJ, Williams KA, Brereton HM. PCR
amplification of the functional immunoglobulin heavy chain variable
gene from a hybridoma in the presence of two aberrant transcripts.
J Immunol Methods 2008;336:246-50.24. Cinek T, Hilgert I, Horejsi V. An alternative way of CD4 and CD8 association
with protein kinases of the Src family. Immunogenetics 1995;41:110-6.
25. Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and
safety. Nanomedicine 2014;9:1025-37.
26. Cregg JM. Introduction: distinctions between Pichia pastoris and other
expression systems. Methods Mol Biol 2007;389:1-10.
27. Bollok M, Resina D, Valero F, Ferrer P. Recent patents on the Pichia
pastoris expression system: expanding the toolbox for recombinant
protein production. Recent Pat Biotechnol 2009;3:192-201.
28. Ridder R, Schmitz R, Legay F, Gram H. Generation of rabbit monoclonal
antibody fragments from a combinatorial phage display library and their
production in the yeast Pichia pastoris. Biotechnology (N Y) 1995;13:255-60.
29. Gasser B, Maurer M, Gach J, Kunert R, Mattanovich D. Engineering of
Pichia pastoris for improved production of antibody fragments.
Biotechnol Bioeng 2006;94:353-61.
30. Jayanna PK, Torchilin VP, Petrenko VA. Liposomes targeted by fusion
phage proteins. Nanomedicine 2009;5:83-9.
31. Bedi D, Musacchio T, Fagbohun OA, Gillespie JW, Deinnocentes P,
Bird RC, et al. Delivery of siRNA into breast cancer cells via phage
fusion protein-targeted liposomes. Nanomedicine 2011;7:315-23.
32. Sabharanjak S, Sharma P, Parton RG, Mayor S. GPI-anchored proteins
are delivered to recycling endosomes via a distinct cdc42-regulated,
clathrin-independent pinocytic pathway. Dev Cell 2002;2:411-23.
33. SapraP,AllenTM. Internalizingantibodiesarenecessary for improved therapeutic
efficacy of antibody-targeted liposomal drugs.Cancer Res 2002;62:7190-4.
